News stories about GTX (NASDAQ:GTXI) have been trending somewhat positive on Sunday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. GTX earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 43.6034888230427 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of equities analysts have recently weighed in on GTXI shares. Stifel Nicolaus started coverage on GTX in a research note on Thursday, November 9th. They set a “buy” rating on the stock. Robert W. Baird started coverage on GTX in a research note on Tuesday, November 21st. They set an “outperform” rating and a $17.00 target price on the stock.

Shares of GTX (NASDAQ GTXI) opened at $11.79 on Friday. The stock has a market capitalization of $235.41, a P/E ratio of -6.74 and a beta of 1.76. GTX has a 12-month low of $2.73 and a 12-month high of $13.35.

GTX (NASDAQ:GTXI) last issued its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.25). equities research analysts anticipate that GTX will post -1.61 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “GTX (GTXI) Receiving Somewhat Favorable Media Coverage, Analysis Finds” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at

GTX Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Insider Buying and Selling by Quarter for GTX (NASDAQ:GTXI)

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with's FREE daily email newsletter.